16th ESO-ESMO Masterclass in Clinical Oncology

Description

Chairs: N. Pavlidis, GR - R.A. Stahel, CH
Scientific Advisors: F. Lordick, DE - R. Popescu, CH

AIMS AND OBJECTIVES
This clinically oriented educational programme has been designed for medical or clinical oncologists who wish to improve their skills or those who are preparing for the national board exam.
The programme will expose participants to a full spectrum of issues in clinical oncology and to practice-oriented training. The programme focuses on breast, colorectal, lung, genito-urinary, gynaecological, head and neck cancers.
Spotlight sessions will facilitate compact update on communication skills, supporting and palliative care, immunotherapy, melanoma, sarcomas and GIST, treatment of elderly cancer patients, molecular tumour boards, magnitude of benefits scale, drug availability, biosimilars, Adolescents and young adults, different roles in the oncology team, ethical dilemmas, low and high grade lymphomas, physical activity.

TEACHING FORMAT
The Masterclass offers plenary lectures regarding state-of-the-art clinical evaluation and treatments with reference to clinical guidelines and which will conclude in take-home messages. Participants will deliver case presentations within tumour boards and small groups and discuss them with the chairmen and the faculty. Informal discussion will be facilitated during the aperitifs with the expert.
All participants will reside at the course venue and participation is compulsory throughout the course. The Masterclass will be entirely in English and fluency in English is necessary for admission. Participants of the concomitant Masterclass in Nursing Oncology will attend selected medical sessions whilst the communication skills sessions will be attended jointly.

THE MASTERCLASS IS
• A 5-day residential educational event
• Full immersion
• Clinically-oriented
• Multidisciplinary
• An international faculty of top experts delivering lectures focusing on genito-urinary, breast, gynaecological, head and neck, gastro-intestinal and lung cancers.

ACCREDITATION
Application for CME recognition will be submitted to the European Society for Medical Oncology (ESMO) for ESMO-MORA accreditation, to the Accreditation Council of Oncology in Europe (ACOE) and to the European Accreditation Council for Continuing Medical Education (EACCME), an institution of the European Union of Medical Specialists (UEMS). EACCME credits are recognised by the American Medical Association towards the Physician’s Recognition Award (PRA).
Information on the status of the applications can be obtained from the organising secretariat.


The Masterclass in Clinical Oncology is an ESO-ESMO joint event


The Masterclass is held in collaboration with the Flims Alumni Club


The 2017 Masterclass is part of the Masterclass-Online Study Program in Advanced Oncology of the University of Ulm

General information

ORGANISING SECRETARIAT
Francesca Marangoni
Ph: +39 02 85464525
Email: fmarangoni@eso.net
European School of Oncology
Via Turati, 29
20121 Milan, Italy
Fax: +39 02 85464545

Applications
Corinne Hall
Ph: +39 02 85464522
Email: chall@eso.net

ACCREDITATION
Application for CME recognition will be submitted to the Accreditation Council of Oncology in Europe (ACOE) and to the European Accreditation Council for Continuing Medical Education (EACCME), an institution of the European Union of Medical Specialists (UEMS). EACCME credits are recognised by the American Medical Association towards the Physician’s Recognition Award (PRA). Information on the status of the applications can be obtained from the organising secretariat.
Furthermore, the conference has been accredited with 25 ESMO-MORA category 1 points.

ACKNOWLEDGEMENTS
The Masterclass is part of the Sharing Progress in Cancer Care programme whose sustaining members are (as of July 2016):
• Platinum member: Bristol-Myers Squibb
• Gold members: Eli Lilly, Genomic Health, Helsinn, Merck KGaA, Darmstadt, Germany, Pfizer and Roche
• Silver members: Bayer, Boehringer Ingelheim, Celgene Corporation, Novartis Oncology, Sandoz Biopharmaceutical and Sanofi

Faculty list

FACULTY (as of July 2016)
M. Aapro, Clinique de Genolier, Oncology Dpt., Genolier, CH
M. Annoni, European Institute of Oncology, Dept. of Biomedical Humanities, Milan, IT
A. Arber, University of Surrey, Faculty of Health and Medical Sciences, Guildford, UK
P. Casali, National Cancer Institute, Medical Oncology Dept., Milan, IT
A. Cervantes Ruiperez, Hospital Clinico Universitario de Valencia - INCLIVA, Haematology and Medical Dept., Valencia, ES
G. Curigliano, European Institute of Oncology, Department of Medicine, Division of Experimental Therapeutics, Milan, IT
A. Dietz, University Hospital Leipzig, ENT Department, Leipzig, DE
M. Dreyling, University Hospital Grosshadern, Dept. of Hematology-Oncology, Munich, DE
A. Eniu, Cancer Institute Ion Chiricuta, Dept. of Breast Cancer, Cluj-Napoca, RO
C. Faivre-Finn, The Christie and University of Manchester, Institute of Cancer Sciences, Manchester, UK
K. Fizazi, Institut Gustave Roussy, Dept. of Cancer Medicine, Villejuif, FR
W. Gatzemeier, Humanitas Cancer Center, Breast Unit, Rozzano, IT
S. Gillessen, Kantospital St. Gallen, Onco-Haematology Clinic, St Gallen, CH
B. Grube, Danish Nurses Organisation, Dept. of Education fro Advanced Cancer Nurses, Copenhagen, DK
S. Hillinger, University Hospital Zurich, Dept. of Thoracic Surgery, Zurich, CH
A. Hoy, Consultant in Palliative Medicine, Epsom, UK United Kingdom
F. Lordick, University Hospital Leipzig, University Cancer Center Leipzig, Leipzig, DE
P. Maugeri, European Institute of Oncology, Dept. of Biomedical Humanities, Milan, IT
G. Mountzios, 251 Airforce General Hospital, Dept. of Medical Oncology, Athens, GR
O. Michielin, Lausanne University Hospital - CHUV, Dept. of Medical Oncology, Lausanne, CH
R. Orecchia, Istituto Europeo di Oncologia, Div. di Radioterapia, Milan, IT
O. Pagani, Oncology Institute of Southern Switzerland (IOSI); Breast Unit, Bellinzona, CH
N. Pavlidis, University Hospital of Ioannina, Div. of Medical Oncology, Ioannina, GR
F. Peccatori, European Institute of Oncology, Dept. of Fertility and Procreation in Oncology, Milan, IT
S. Peters, Centre Hospitalier Universitaire Vaudois, Dept. of Oncology, Lausanne, CH
R. Popescu, Hirslanden Klinik Aarau, Tumor Center - Dept. of Medical Oncology, Aarau, CH
G. Pruneri, European Institute of Oncology, Dept. Of Pathology, Milan, IT
M. Roobol, Erasmus University Medical Center, Dept. of Urology/Epidemiology, Rotterdam, NL
V. Sanchini, European Institute of Oncology, Dept. of Biomedical Humanities, Milan, IT
M. Schmidinger, Medical University of Vienna, Internal Medicine Clinic I - Dept. of Oncology, Vienna, AT
D. Sebag-Montefiore, St James' Institute of Oncology - St James' University Hospital, Dept. of Oncology, Leeds, UK
J. Sehouli, Charité Medical University, Gynaecological Clinic, Berlin , DE
C. Sessa, Oncology Institute of Southern Switzerland, Div. of Medical Oncology, Bellinzona, CH
R. Stahel, University Hospital Zurich, Clinic for Oncology, Zurich, CH
E. Van Cutsem, University Hospital Leuven, Digestive Oncology Dpt., Leuven, BE
E. van Muilekom, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Urology Dpt., Amsterdam, NL
J. Vermorken, Antwerp University Hospital, Dept. of Medical Oncology, Edegem, BE
Y. Wengström, Karolinska Insitutet, Department of Neurobiology, Care Science and Society, Div of Nursing, Huddinge, SE
C. Zielinski, Comprehensive Cancer Center Vienna, Clinical Division of Oncology, Vienna, AT

Programme

25 March


		Participants' arrival, airport transfers, registration
12:30		Lunch
13:45		Focus on ESO, ESMO and EONS F.A. Peccatori, IT - R.A. Stahel, CH - B. Grube, DK
		PARALLEL SESSIONS
14:15		Communication Skills Workshop - 2 Groups A. Arber, UK - A. Hoy, UK
14:15		Warm up + Case presentations by participants R.A. Stahel, CH - R. Popescu, CH
15:45		Coffee break
16:00		Communication Skills Workshop - 2 Groups A. Arber, UK - A. Hoy, UK
16:00		Warm up + Case presentations by participants N. Pavlidis, GR - R. Popescu, CH
17:30		Coffee break
17:45		Communication Skills Workshop - 2 Groups A. Arber, UK - A. Hoy, UK
17:45		Warm up + Case presentations by participants N. Pavlidis, GR - R.A. Stahel, CH
20:00		Dinner

26 March


8:30		Clinical session Lung cancer I Chair: R.A. Stahel, CH
		Surgery S. Hillinger, CH Radiotherapy C. Faivre-Finn, UK Chemotherapy and targeted treatment R.A. Stahel, CH Immunotherapy of NSCLC S. Peters, CH Small cell lung cancer C. Faivre-Finn, UK *Discussion after each lecture*
11:00		Coffee break
11:30		Tumour board Lung cancer R.A. Stahel, CH - C. Faivre-Finn, UK - S. Peters, CH
12:30		Spotlight session Supportive and palliative care (including early integration of palliative care) M. Aapro, CH
12:50		*Discussion*
13:00		Lunch
14:00		Spotlight session Immunotherapy O. Michielin, CH
14:30		Discussion
14:40		Spotlight session Melanoma O. Michielin, CH
15:10		Discussion
15:20		Spotlight session - Sarcomas and GIST P. Casali, CH
16:00		Spotlight session Treatment of elderly cancer patients M. Aapro, CH
16:20		Discussion
18:30		Aperitif with the experts
19:30		Dinner

27 March


8:30		Clinical session Gastro-intestinal tumours Chair: D. Sebag-Montefiore, UK
		Systemic treatment in adjuvant setting in colon cancer A. Cervantes, ES Systemic treatment in advanced colon cancer E. van Cutsem, BE Management of rectal cancer (surgery and radiotherapy) D. Sebag-Montefiore, UK Systemic treatment in early and advanced gastric cancer F. Lordick, DE Pancreatic cancer R. Popescu, CH Discussion after each session
11:00		Coffee break
11:30		Tumour board Gastro-intestinal tumours (2 participants' cases + 1 faculty case) A. Cervantes, ES - D. Sebag-Montefiore, UK - E. van Cutsem, BE - R. Popescu, CH - F. Lordick, DE
12:30		Spotlight session Molecular tumour boards C. Zielinski, AT
12:50		Discussion
13:00		Lunch
14:00		Case presentations by participants N. Pavlidis, GR - R.A. Stahel, CH - R. Popescu, CH
15:30		Spotlight session Magnitude of benefits scale C. Zielinski, AT
15:50		Discussion
16:00		Spotlight session Drug availability A. Eniu, RO
16:20		Discussion
18:30		Aperitif with the experts
19:30		Dinner

28 March


8:30		Clinical session Breast cancer Chair: G. Curigliano, IT
		Pathology G. Pruneri, IT Surgery W. Gatzemeier, IT Radiotherapy R. Orecchia, IT Treatment of Luminal O. Pagani, CH Treatment of HER-2+ A. Eniu, RO Treatment of triple negative G. Curigliano, IT Discussion after each session
11:00		Coffee break
11:30		Tumour board Breast cancer (2 participants' cases + 1 faculty case) G. Curigliano, IT - O. Pagani, CH - W. Gatzemeier, AT - R. Orecchia, IT - G. Pruneri, IT - A. Eniu, RO
12:30		Spotlight session Biosimilars G. Curigliano, IT
12:50		*Discussion*
13:00		Lunch
14.00		Spotlight session Adolescents and young adults G. Mountzios, GR
14:20		*Discussion*
14:30		Spotlight session Different roles in the oncology team E. van Muilekom
14:50		Discussion
		ETHICAL DILEMMAS WORKSHOP
15:00		Introduction and presentation of the workshop V. Sanchini, IT - P. Maugeri, IT - M. Annoni, IT
15:20		Parallel sessions: Interactive workshop on ethical dilemmas (6 groups) V. Sanchini, IT - P. Maugeri, IT - M. Annoni, IT
16:00		Sum-up on ethical dilemmas V. Sanchini, IT - P. Maugeri, IT - M. Annoni, IT
16:30		Discussion
18:30		Aperitif with the experts
19:30		Dinner + party

29 March


8:30		Clinical session Genito-urinary cancers Chair: K. Fizazi, FR Diagnosis and active surveillance in prostate cancer M. Roobol, NL Initial hormone therapy for metastatic prostate cancer S. Gillessen, CH Castration-resistant prostate cancer K. Fizazi, FR Metastatic renal cancer: evidence-based treatment M. Schmidinger, CH Treatment of bladder cancer S. Gillessen, CH Discussion after each session
11:30		Coffee break
12:00		Tumour board Genito-urinary cancers (2 participants' cases + 1 faculty case) K. Fizazi, FR - S. Giellessen, CH - M. Schmidinger, CH - M. Roobol, NL
13:00		Lunch
14:00		Clinical session Head and neck cancer Chair: Jan B. Vermorken, NL
		Prognostic factors and surgical approach A. Dietz, DE Radiotherapy R. Orecchia, IT Systemic therapy and radio- chemo-therapy J.B. Vermorken, NL *Discussion after each session*
15:45		Tumour board Head & Neck cancer (1 participants' case + 1 faculty case) J.B. Vermorken, NL - R. Orecchia, IT - A. Dietz, DE
16:15		Coffee break
16:45		Spotlight session Low and high grade lymphomas: recent therapeutic advances M. Dreyling, DE
16:20		Discussion
18:30		Aperitif with the experts
19:30		Dinner

30 March


8:30		Clinical session Gynaecological cancers Chair: J.B. Vermorken, BE
		Surgery J. Sehouli, DE Ovarian cancer J.B. Vermorken, BE Cervical and endometrial cancers C. Sessa, CH Discussion at the end of each lecture
10:30		Tumour board Gynaecological cancers J.B. Vermorken, BE - C. Sessa, CH - J. Sehouli, DE
11:00		Coffee break
11:30		Learning assessment test
12:30		Spotlight session Physical Activity / Exercise and Cancer Y. Wengström, SE
12:50		*Discussion*
13:00		Closing remarks